#Biotech Clinical Data in Q3/Q4 14 ..Updated $ACST end Q3 ph2 $AVNR P3-late Q3 $CPRX Firdapse Ph 3-Aug/Sept $ICPT P2 Flint-Aug $Xoma (XOMA) Clinical Ph 3 EYEGUARD-B data for Gevokizumab in Behcet's uveitis (Aug/Sept) $OXGN-P2 9/26 GOG $SNSS-late Q3/early Q4 Valor Data due. $THLD P3 interim (Mid-Sept) $TRGT P2-Q4 $TNXP TNX-102 Q4
-Aug 10-13 Epizyme (EPZM) Clinical Preliminary data from Ph 1 trial of EPZ-6438 at ASH Meeting on Lymphoma Biology
Aug Intercept (ICPT) Clinical Full data incl. 24-week follow-up from Ph 2 FLINT trial of OCA in NASH
end of Q3:14 Anacor (ANAC) Commercial US launch of Kerydin for onychomycosis
Aug/Sep Xoma (XOMA) Clinical Ph 3 EYEGUARD-B data for Gevokizumab in Behcet's uveitis
Sept 7th PDUFA-$KERX for Zerenex
Sept 11 Infinity (INFI) and Regulatory PDUFA date for Idelalisib (competitor to IPI-145 and Imbruvica) from Gilead for non-Hodgkin's lymphoma Pharmacyclics (PCYC)
Sept 11th PDUFA-$OREX for Contrave
Sept 12 NPS (NPSP) Regulatory FDA Advisory Committee to discuss BLA for Natpara (recombinant parathyroid hormone)
Sept 10-13 Receptos (RCPT) Clinical Potential presentation of full Ph 2 RADIANCE data at ACTRIMS-ECTRIMS meeting
Sept 16th-$NKTR PDUFA
Sept 18 Medivation (MDVN) Regulatory PDUFA date for sNDA for Xtandi in pre-chemo metastatic CRPC
Sept26-30 Endocyte (ECYT) Clinical Updated data from Ph 2b TARGET study of vintafolide in folate-receptor positive NSCLC presented at ESMO
Sept 26th PDUFA Date for $PSDV/ALIM
Nov 5th PDUFA Date for $AEZS (AEZS-130 for AGHD)
H2:14 Fate (FATE) Clinical Interim update from Ph 2 PUMA study of ProHema in patients with hematologic malignancies
H2:14 Novavax (NVAX) Clinical Top-line data from Ph 1/2 trial of H7N9 avian flu VLP vaccine with Matrix-M adjuvant
H2:14 NPS (NPSP) Commercial European launch of Revestive (Gattex)
H2:14 Omeros (OMER) Comm/Reg US Launch and potential EU approval for Omidria
H2:14 Pharmacyclics (PCYC) Clinical Data from Ph 2 trials of Imbruvica in MM and CLL/SLL patients with 17p deletion (RESONATE-17)
H2:14 Sunesis (SNSS) Regulatory Top-line data from Ph 3 VALOR trial of vosaroxin
H2:14 Xencor (XNCR) Clinical Top-line data from Ph 2 trials of MOR208 in ALL and XmAb5871 in rheumatoid arthritis
H2:14 Xoma (XOMA) Commercial Potential partnership for XMet program in diabetes
Oct 7 Pharmacyclics (PCYC) Regulatory PDUFA date for Imbruvica for r/r CLL/SLL (already approved under accelerated pathway)
Oct 24 NPS (NPSP) Regulatory PDUFA date for Natpara for hypoparathyroidism
Nov 7-11 Intercept (ICPT) Clinical Detailed FLINT Ph 2b OCA/NASH results at AASLD in Boston
Nov 11-16 La Jolla (LJPC) Clinical Detailed results of Ph 2a trial of GCS-100 in CKD at American Society of Nephrology meeting
Nov 13-16 Celldex (CLDX) Clinical updated data from Ph 2 ReACT trial of rindopepimut in recurrent glioblastoma presented at SNO meeting
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.